Alzheimer's disease

First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
CP Wire
Alzheimer's disease
simulation
drug discovery
SIAM News
Duke University
Penn State University
Flag link:
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Alzheimer's disease
simulation
drug discovery
SIAM News
Duke University
Penn State University
Flag link:
A year after Roche's Alzheimer's failure, scientists reflect on what could have been
A year after Roche's Alzheimer's failure, scientists reflect on what could have been
Fierce Biotech
Roche
Genentech
Alzheimer's disease
gantenerumab
Flag link:
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Biogen's M&A, Alzheimer's drug launch costs spark profit forecast cut
Reuters
Biogen
Alzheimer's disease
Leqembi
Reata
M&A
earnings
Flag link:
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March
Eisai expects Alzheimer's drug to rake in revenue of $66.5 million by March
Reuters
Eisai
Leqembi
Alzheimer's disease
Flag link:
Co-developer of Cassava’s potential Alzheimer’s drug cited for ‘egregious misconduct’
Co-developer of Cassava’s potential Alzheimer’s drug cited for ‘egregious misconduct’
Science
Cassava Sciences
Alzheimer's disease
Simulfilam
clinical trials
Flag link:
Doubts abound about a new Alzheimer’s blood test
Doubts abound about a new Alzheimer’s blood test
Medical Marketing and Media
diagnostics
Quest Diagnostics
Medtech
Alzheimer's disease
AD-Detect
Flag link:
Merck terminates Phase II trials for Alzheimer’s drug due to liver toxicity
Merck terminates Phase II trials for Alzheimer’s drug due to liver toxicity
Clinical Trials Arena
Merck
clinical trials
MK-1942
liver toxicity
Alzheimer's disease
Flag link:
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi
BioPharma Dive
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Araclon vaccine appears to slow Alzheimer's in exploratory phase 2 analysis, spurring review of next steps
Araclon vaccine appears to slow Alzheimer's in exploratory phase 2 analysis, spurring review of next steps
Fierce Biotech
Araclon
Grifols
Alzheimer's disease
clinical trials
vaccines
ABvac40
Flag link:
CuraSen to bring new Alzheimer’s drug into trial in 2024
CuraSen to bring new Alzheimer’s drug into trial in 2024
Clinical Trials Arena
CuraSen Therapeutics
clinical trials
CST-3056
Alzheimer's disease
Flag link:
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
As 'harvest time' arrives for Alzheimer's, neuroscientist reflects on next steps for drug development
Fierce Biotech
Alzheimer's disease
Biogen
Eisai
Eli Lilly
Leqembi
donanemab
Flag link:
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit
Fierce Pharma
Biogen
Aduhelm
legal
Eisai
Alzheimer's disease
Flag link:
Labcorp launches 3-part blood test for Alzheimer's
Labcorp launches 3-part blood test for Alzheimer's
Reuters
LabCorp
Medtech
diagnostics
biomarkers
Alzheimer's disease
Flag link:
Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A
Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A
Fierce Biotech
AstronauTx
Novartis
Alzheimer's disease
Flag link:
Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study
Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study
Benzinga
Longeveron
clinical trials
Alzheimer's disease
lomacel-B
Flag link:
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Fierce Biotech
Roche
Ionis Pharmaceuticals
RNA
Alzheimer's disease
Huntington's disease
Flag link:
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
Flag link:
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
BioSpace
Cassava Sciences
clinical trials
Simulfilam
Alzheimer's disease
Flag link:
Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients
Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients
BioSpace
Anavex
Alzheimer's disease
blarcamesine
clinical trials
Flag link:

Pages